Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth

XUESONG LIU, JESSICA POWLAS, YAN SHI, ANATOL X. OLEKSIJEW, ALEXANDER R. SHOEMAKER, RON DE JONG, TILMAN OLTERSDORF, VINCENT L. GIRANDA and YAN LUO
Anticancer Research September 2004, 24 (5A) 2697-2704;
XUESONG LIU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JESSICA POWLAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YAN SHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANATOL X. OLEKSIJEW
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDER R. SHOEMAKER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RON DE JONG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TILMAN OLTERSDORF
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VINCENT L. GIRANDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YAN LUO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Akt is a serine/threonine kinase that plays a critical role in cell survival and proliferation. Three isoforms of Akt have been identified and have been shown to be up-regulated in human malignancies. We examined the requirement of these pathways for Akt transformation. We generated NIH-3T3 cells over-expressing constitutively active Myr-Akt1 (3T3-Akt1 cells) or Myr-Akt2 (3T3-Akt2 cells). These cells are able to form colonies in soft-agar and 3T3-Akt1 cells formed tumors in SCID mice. Rapamycin efficiently inhibited the activation of the mTOR-p70S6K pathway and the anchorage-independent growth of both 3T3-Akt cells, demonstrating the importance of the mTOR-p70S6K pathway for transformation by Akt1 as well as by Akt2. Moreover, rapamycin dramatically inhibited the tumor formation by 3T3-Akt1 cells in SCID mice. Thus, we demonstrated the importance of mTOR-p70S6 kinase pathway in the transformation by Akt, both in tissue-cultured cells and in animal tumor models. In contrast, neither the MAPK pathway nor the p38 MAPK pathway is required for Akt-dependent transformation of NIH3T3 cells.

Footnotes

    • Received July 12, 2004.
    • Accepted July 27, 2004.
  • Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 24, Issue 5A
September-October 2004
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth
XUESONG LIU, JESSICA POWLAS, YAN SHI, ANATOL X. OLEKSIJEW, ALEXANDER R. SHOEMAKER, RON DE JONG, TILMAN OLTERSDORF, VINCENT L. GIRANDA, YAN LUO
Anticancer Research Sep 2004, 24 (5A) 2697-2704;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth
XUESONG LIU, JESSICA POWLAS, YAN SHI, ANATOL X. OLEKSIJEW, ALEXANDER R. SHOEMAKER, RON DE JONG, TILMAN OLTERSDORF, VINCENT L. GIRANDA, YAN LUO
Anticancer Research Sep 2004, 24 (5A) 2697-2704;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways
  • Excessive glucocorticoid-induced muscle MuRF1 overexpression is independent of Akt/FoXO1 pathway
  • Spleen Tyrosine Kinase (Syk), a Novel Target of Curcumin, Is Required for B Lymphoma Growth
  • Quantitative Analysis of Anti-apoptotic Function of Akt in Akt1 and Akt2 Double Knock-out Mouse Embryonic Fibroblast Cells under Normal and Stressed Conditions
  • Google Scholar

More in this TOC Section

  • Targeted Sensitization of Leukemic T-cells to Anticancer Drugs by SIRT1 Agonist SRT-1720
  • Alteration of Flavin Homeostasis in Uterine Cancer
  • Prognostic Significance of PPFIA2 in Localized Prostate Cancer: Integrative Analysis and Functional Validation
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire